Cancer immunotherapy can harness the specificity of immune response to target and
eliminate tumors. Adoptive cell therapy (ACT) based on the adoptive transfer of T cells
genetically modified to express a chimeric antigen receptor (CAR) has shown considerable
promise in clinical trials1-4. There are several advantages to using CAR+ T cells for the
treatment of cancers including the ability to target non-MHC restricted antigens and to
functionalize the T cells for optimal survival, homing and persistence within the host; and …